Affymetrix signs translational medicine agreement in China

By Elaine Rigoli

Tampa, Fla., Sept. 18 - Affymetrix, Inc. and Zhejiang California Nanosystem Institute have entered into a collaboration to develop clinical applications using GeneChip technology.

Under the agreement, Zhejiang researchers will use Affymetrix GeneChip microarray technology for translational medicine research projects, beginning with cancer, newborn genetic diseases and infectious diseases.

In addition, the two organizations are establishing a joint laboratory that will support clinical researchers at Zhejiang University and its six affiliated hospitals. The researchers will use GeneChip technology to analyze genomic information across large patient samples.

This is the Santa Clara, Calif., biotechnology company's first translational medicine collaboration in China.

Zhejiang California International Nanosystem Institute is a technology innovation platform in China established in June 2005. It is a joint effort among Zhejiang Provincial Government, Zhejiang University and California NanoSystems Institute.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.